- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04352933
PROLIFIC ChemoprophylaxisTrial (COVID-19)
ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial)
Visão geral do estudo
Status
Condições
Descrição detalhada
The number of confirmed cases of COVID-19 infectious disease arising from the SARS-CoV-2 coronavirus is rising substantially and rapidly, with the potential to overwhelm the ability of the entire National Health Service (NHS) to cope with the increased demand. The availability of personal protective equipment is limited and reports of high risk procedures such as aerosol generating procedures (e.g. intubation for the sickest patients) is a source of great concern for infection transmission. Frontline NHS staff with direct patient contact have the highest likelihood of exposure to SARS-CoV-2 and development of COVID-19 disease. Efforts to protect these workers from development of COVID-19, using drugs to prevent the disease, require urgent evaluation.
This trial will be a double-blind, randomized, placebo-controlled trial in a cohort of frontline healthcare workers, who will potentially be exposed to SARS-CoV-2. Eligible participants will be frontline NHS workers aged 18 to 70 years who work in a healthcare setting with direct patient care. Participants will be randomised to one of 3 arms and receive either: (1) Hydroxychloroquine Daily (loading phase: 800mg for first 2 days; maintenance phase: 1 x 200mg tablet every day) + weekly placebo; (2) Hydroxychloroquine weekly (loading phase: 800mg for first 2 days; maintenance phase: 2 x 200mg tablets every 7th day/weekly) + daily placebo, or (3) placebo (daily and weekly).
Participants will be reviewed at an interim visit 6 weeks after baseline and again and the end of the study treatment in 90 days (approximately 3 months) after randomization. Participants will also complete brief questions about their health weekly while on treatment (remotely, via app/web/phone-based interface).
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Cambridge, Reino Unido, CB2 0QQ
- Recrutamento
- Cambridge University Hospitals NHS Foundation Trust
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
To be included in the trial the participant MUST:
- Have given written informed consent to participate
- Be aged 18 years to 70 years
- Not previously have been diagnosed with COVID-19
- Work in a high-risk secondary or tertiary healthcare setting (hospitals accepting COVID-19 patients) with direct patient-facing care
Exclusion Criteria:The presence of any of the following will mean participants are ineligible:
- Known COVID-19 positive test at baseline (if available)
- Symptomatic for possible COVID-19 at baseline
- Known hypersensitivity reaction to HCQ, chloroquine or 4-aminoquinolines
- Known retinal disease
- Known porphyria
- Known chronic kidney disease (CKD; eGFR<30ml/min)
- Known epilepsy
- Known heart failure or conduction problems
- Known significant liver disease (Gilbert's syndrome is permitted)
- Known glucose-6-phosphate dehydrogenase (G6PD) deficiency
Currently taking any of the following contraindicated medications:
- Digoxin
- Chloroquine
- Halofantrine
- Amiodarone
- Moxifloxacin
- Cyclosporin
- Mefloquine
- Praziquantel
- Ciprofloxacin
- Clarithromycin
- Prochlorperazine
- Fluconazole
- Currently taking hydroxychloroquine or having a clinical indication for taking hydroxychloroquine
- Currently breastfeeding
- Unable to be followed-up during the trial
- Current or future involvement in the active treatment phase of other interventional research studies (excluding observational/non-interventional studies) before study follow-up visit
- Not able to use or have access to a modern phone device/web-based technology
- Any other clinical reason which may preclude entry in the opinion of the investigator
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador Ativo: Hydroxychloroquine - Daily dosing
Hydroxychloroquine Daily (loading phase: 800mg for first 2 days; maintenance phase: 1 x 200mg tablet every day) + weekly placebo, for approximately 90 days. Route: Oral. Pharmaceutical form: Tablet |
Active HCQ: Days 1-2: Loading phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 200mg (1 x 200mg capsule) taken ONCE A DAY, every day for 90 days (~3 months), Matched Placebo HCQ: Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (~3 months) |
Comparador Ativo: Hydroxychloroquine - Weekly dosing
Hydroxychloroquine weekly (loading phase: 800mg for first 2 days; maintenance phase: 2 x 200mg tablets every 7th day/weekly) + daily placebo, for approximately 90 days. Route: Oral. Pharmaceutical form: Tablet |
Active HCQ: Days 1-2: Loading Phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 400mg (2 x 200mg capsules) taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (~3 months) Matched Placebo HCQ: Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (~3 months) |
Comparador de Placebo: Placebo
Placebo arm - 2 tablets twice daily for first 2 days (loading phase), followed by 1 tablet every day for 90 days plus 2 tablets every 7th day, for approximately 90 days. Route: Oral. Pharmaceutical form: Tablet |
Matched placebo HCQ - daily dosing: Days 1-2: Loading Phase - 2 capsules taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (~3 months) Matched placebo HCQ - weekly dosing Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (~3 months) |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Time to positive COVID-19 disease
Prazo: Assessed up to 90 days
|
Time taken for incidence of COVID-19 disease between Hydroxychloroquine and placebo arms
|
Assessed up to 90 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Number of COVID-19 test positive cases
Prazo: Assessed up to 90 days
|
Number of COVID-19 symptoms based on clinical guidelines and test positive infections per study arm
|
Assessed up to 90 days
|
Number of COVID-19 serological test positive cases
Prazo: Assessed up to 90 days
|
Number of test positive COVID-19 serological test positive cases per study arm
|
Assessed up to 90 days
|
Severity of COVID-19 disease between each arm
Prazo: Assessed up to 90 days
|
Severity based on hospitalisation
|
Assessed up to 90 days
|
Number of common COVID-19 complications between each arm
Prazo: Assessed up to 90 days
|
Number of common COVID-19 complications between arms
|
Assessed up to 90 days
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções por coronavírus
- Infecções por Coronaviridae
- Infecções por Nidovírus
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções do Trato Respiratório
- Doenças Respiratórias
- Pneumonia Viral
- Pneumonia
- Doenças pulmonares
- COVID-19
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Inibidores Enzimáticos
- Agentes Antirreumáticos
- Agentes Antiprotozoários
- Antiparasitários
- Antimaláricos
- Hidroxicloroquina
Outros números de identificação do estudo
- PROLIFIC2020 (A095583)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em COVID-19
-
Yang I. PachankisAtivo, não recrutandoInfecção Respiratória COVID-19 | Síndrome de Estresse COVID-19 | Reação adversa à vacina COVID-19 | Tromboembolismo associado à COVID-19 | Síndrome Pós-Cuidados Intensivos COVID-19 | AVC associado à COVID-19China
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...ConcluídoSequelas pós-agudas de COVID-19 | Condição pós-COVID-19 | Longo-COVID | Síndrome COVID-19 CrônicaItália
-
Massachusetts General HospitalRecrutamentoSíndrome pós-aguda de COVID-19 | Longo COVID | Sequelas pós-agudas de COVID-19 | Longo COVID-19Estados Unidos
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkAinda não está recrutandoSíndrome pós-COVID-19 | Longo COVID | Longo Covid19 | Condição pós-COVID-19 | Síndrome pós-COVID | Condição pós-COVID-19, não especificada | Condição Pós-COVIDHolanda
-
Indonesia UniversityRecrutamentoSíndrome pós-COVID-19 | Longo COVID | Condição pós-COVID-19 | Síndrome pós-COVID | Longo COVID-19Indonésia
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... e outros colaboradoresRecrutamentoCOVID-19 | Síndrome pós-COVID-19 | Pós-Agudo COVID-19 | COVID-19 agudoChina
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyConcluídoSíndrome pós-COVID-19 | Síndrome de Longo-COVID-19Alemanha
-
Medisch Spectrum TwenteZiekenhuisgroep Twente; University of TwenteAtivo, não recrutando
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecrutamentoPneumonia COVID-19 | Infecção Respiratória COVID-19 | Pandemia do covid-19 | Síndrome do Desconforto Respiratório Agudo COVID-19 | Pneumonia associada à COVID-19 | Coagulopatia Associada à COVID 19 | COVID-19 (doença de coronavírus 2019) | Tromboembolismo associado à COVID-19Grécia
Ensaios clínicos em Hydroxychloroquine - Daily dosing
-
Semaine HealthCitruslabsConcluídoDistúrbio HormonalEstados Unidos
-
Galderma R&DConcluídoIrritação na peleEstados Unidos
-
Birmingham Community Healthcare NHSNSA, LLCConcluído
-
GlookoConcluídoDiabetes mellitus tipo 2Estados Unidos
-
Bausch & Lomb IncorporatedConcluídoAstigmatismo | MiopiaEstados Unidos
-
KGK Science Inc.Neogenis LaboratoriesRescindido
-
Bausch & Lomb IncorporatedConcluído
-
Alcon ResearchConcluídoErro RefrativoReino Unido
-
Hospices Civils de LyonRecrutamento
-
TCI Co., Ltd.ConcluídoCondição de peleTaiwan